Open AccessSingle nucleotide polymorphism MTHFR677C>T and the severity of metabolic side effects of antipsychotics in patients with schizophrenia: the results of a pilot study
Author(s) -
M. A. Kosataya,
A. V. Marina,
А. В. Сергеева,
Г. Э. Мазо,
А С Благонравова,
Г. Э. Мазо
Publication year - 2018
Publication title -
obozrenie psihiatrii i medicinskoj psihologii im. v.m. behtereva/obozrenie psihiatrii i medicinskoj psihologii imeni v.m. behtereva
Language(s) - English
Resource type - Journals
eISSN - 2713-055X
pISSN - 2313-7053
DOI - 10.31363/2313-7053-2018-3-40-46
Subject(s) - single nucleotide polymorphism , allele , medicine , metabolic syndrome , schizophrenia (object oriented programming) , polymorphism (computer science) , genetics , bioinformatics , oncology , psychiatry , genotype , biology , obesity , gene
To predict the development of side effects and personalized selection of drug therapy, it seems relevant to study the association of individual genetic risk factors with undesirable side effects of antipsychotics in chronic patients with schizophrenia. Thereby the purpose of this study was to evaluate the association between the carriage of the T-allele of the single nucleotide genetic polymorphism MTHFR677C>T and the severity of the metabolic side effects of antipsychotics. As a result of the study a greater risk of developing components of the metabolic syndrome was revealed, as well as a significantly higher fasting blood glucose level in the group of carriers of the minor T-allele of polymorphism MTHFR677C>T.